ELDN — Eledon Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $186.90m
- $137.16m
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial
Health Rounds: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial
Brief: Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes (T1d) At Uchicago Medicine
Brief: Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results And Recent Business Highlights
Eledon Pharmaceuticals Q1 net loss widens on warrant liability loss
Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs
Brief: Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At Uchicago Medicine
U.S. STOCKS ON THE MOVE-Nuwellis, Citigroup, Meta
U.S. STOCKS ON THE MOVE-GE Vernova, Atlas Energy, Citigroup
U.S. STOCKS ON THE MOVE-Rivian, Bunge, Vertex
U.S. STOCKS ON THE MOVE-Crypto stocks, MiNK Therapeutics, AtaiBeckley
Eledon rises as FDA grants orphan drug status for liver transplant rejection drug
Brief: Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant
Immune therapy developer Eledon Pharmaceuticals swings to Q3 net loss
Brief: Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering Of Common Stock And Pre-Funded Warrants
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary